ABSTRACT
BACKGROUND: We report that R- and S-phenibut (ß-phenyl-γ-aminobutyric acid) - derivatives of GABA - bind with an affinity of c.a. 90µM to the gabapentin binding site in a competitive assay, a value comparable to that for previously claimed targets for this enantioermic molecule. This finding implied potential activity in neuropathic pain, this being one of the clinically validated indications for gabapentin. METHODS: The effect of phenibut on tactile allodynia was tested in a chronic constriction nerve injury (CCI) neuropathic pain model and against hypersensitivity following inflammation induced by inoculation using complete Freund's adjuvant (CFA) model. RESULTS: Indeed, a significant inhibitory effect on tactile allodynia was detected in rats in both employed chronic pain models with stronger and clearly dose dependent effect with R isomer. CONCLUSIONS: The results confirm activity in chronic pain models predicted from affinity for the gabapentin site and suggests, at least partially, that α2δ-subunits of presynaptic voltage-gated calcium channels are involved in mediating this effect.
Subject(s)
Amines/antagonists & inhibitors , Chronic Pain/drug therapy , Cyclohexanecarboxylic Acids/antagonists & inhibitors , gamma-Aminobutyric Acid/analogs & derivatives , Animals , Disease Models, Animal , Freund's Adjuvant , Gabapentin , Hypersensitivity/drug therapy , Male , Pain Measurement/drug effects , Radioligand Assay , Rats , Stereoisomerism , gamma-Aminobutyric Acid/pharmacology , gamma-Aminobutyric Acid/therapeutic useABSTRACT
It has been proposed that activation of metabotropic glutamate receptor subtype 2/3 (mGluR2/3) may induce both antipsychotic and anxiolytic effects. The aim of this study was to evaluate further the effect of the mGluR2/3 agonist, LY354740 [(+)-2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylate monohydrate] in animal models relevant to both psychotic and cognitive impairment in schizophrenia. The elevated plus maze was used to select the doses for further experiments, LY354740 induced anxiolytic-like effects at doses of 3 and 10 mg/kg but not 1 mg/kg. At a dose of 10 mg/kg. LY354740 attenuated phencyclidine (PCP)-induced locomotor activity. Administered alone, it had no effect on horizontal activity, but at doses of 3 and 10 mg/kg, slightly decreased vertical activity (rearings). LY354740 (1-10 mg/kg intraperitoneally) affected neither prepulse inhibition in normal rats nor reversed the disruption of prepulse inhibition produced by PCP (2 mg/kg subcutaneously). Moreover, LY354740 (3-10 mg/kg) did not modify PCP-induced working memory deficits assessed in a spontaneous alternation task and had no effect on PCP-evoked amnesia in the passive avoidance test. LY354740 alone (3 and 10 mg/kg) induced working memory deficits, but had no effect on acquisition of passive avoidance. In conclusion, LY354740 was effective in models for anxiety and positive symptoms of schizophrenia but not in models for sensorimotor gating and cognitive impairment.
Subject(s)
Anti-Anxiety Agents/pharmacology , Bridged Bicyclo Compounds/pharmacology , Cognition/drug effects , Receptors, Metabotropic Glutamate/agonists , Schizophrenia/drug therapy , Schizophrenic Psychology , Animals , Avoidance Learning/drug effects , Behavior, Animal/drug effects , Disease Models, Animal , Drug Evaluation, Preclinical , Excitatory Amino Acid Agonists/pharmacology , Exploratory Behavior/drug effects , Male , Maze Learning/drug effects , Motor Activity/drug effects , Rats , Rats, Sprague-Dawley , Reflex, Startle/drug effectsABSTRACT
L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson patients after a prolonged treatment with levodopa (L-DOPA). Since previous transcriptome and proteomic studies performed in the rat model of LID suggested important changes in striatal energy-related components, we hypothesize that oral creatine supplementation could prevent or attenuate the occurrence of LID. In this study, 6-hydroxydopamine-lesioned rats received a 2% creatine-supplemented diet for 1 month prior to L-DOPA therapy. During the 21 days of L-DOPA treatment, significant reductions in abnormal involuntary movements (AIMs) have been observed in the creatine-supplemented group, without any worsening of parkinsonism. In situ hybridization histochemistry and immunohistochemistry analysis of the striatum also showed a reduction in the levels of prodynorphin mRNA and FosB/DeltaFosB-immunopositive cells in creatine-supplemented diet group, an effect that was dependant on the development of AIMs. Further investigation of the bioenergetics' status of the denervated striatum revealed significant changes in the levels of creatine both after L-DOPA alone and with the supplemented diet. In conclusion, we demonstrated that combining L-DOPA therapy with a diet enriched in creatine could attenuate LID, which may represent a new way to control the motor complications associated with L-DOPA therapy.
Subject(s)
Creatine/metabolism , Dyskinesia, Drug-Induced/metabolism , Energy Metabolism/physiology , Neostriatum/metabolism , Neuroprotective Agents/metabolism , Administration, Oral , Analysis of Variance , Animals , Creatine/administration & dosage , Dietary Supplements , Disease Models, Animal , Dyskinesia, Drug-Induced/complications , Dyskinesia, Drug-Induced/prevention & control , Enkephalins/genetics , Enkephalins/metabolism , Female , In Vitro Techniques , Levodopa/adverse effects , Levodopa/therapeutic use , Neostriatum/drug effects , Neuroprotective Agents/administration & dosage , Oxidopamine , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/complications , Parkinsonian Disorders/drug therapy , Phosphocreatine/metabolism , Protein Precursors/genetics , Protein Precursors/metabolism , Proto-Oncogene Proteins c-fos/genetics , Proto-Oncogene Proteins c-fos/metabolism , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Statistics, NonparametricABSTRACT
N-acetylated-alpha-linked-acidic peptidase (NAAG peptidase) converts N-acetyl-aspartyl-glutamate (NAAG, mGluR3 agonist) into N-acetyl-aspartate and glutamate. The NAAG peptidase inhibitor 2-PMPA (2-(phosphonomethyl)pentanedioic acid) had neuroprotective activity in an animal model of stroke and anti-allodynic activity in CCI model despite its uncertain ability to penetrate the blood-brain barrier. The NAAG concentration in brain ECF under basal conditions and its alteration in relation to the brain ECF concentration of 2-PMPA is unclear. We therefore assessed those brain concentrations after i.p. administration of 2-PMPA, using in vivo microdialysis combined with LC/MS/MS analysis. Administration of 2-PMPA (50mg/kg) produced a mean peak concentration of 2-PMPA of 29.66+/-8.1microM. This concentration is about 100,000 fold more than is needed for inhibition of NAAG peptidase, and indicates very good penetration to the brain. Application of 2-PMPA was followed by a linear increase of NAAG-concentration reaching a maximum of 2.89+/-0.42microM at the end of microdialysis. However, during the time the anti-allodynic effects of 2-PMPA were observed, the NAAG concentration in the ECF did not reach levels which are likely to have an impact on any known target. It appears therefore that the observed behavioural effects of 2-PMPA may not be mediated by NAAG nor, in turn, by mGluR3 receptors.
Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Brain Chemistry/drug effects , Glutamate Carboxypeptidase II/antagonists & inhibitors , Neuralgia/drug therapy , Neuroprotective Agents/therapeutic use , Organophosphorus Compounds/therapeutic use , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/pharmacokinetics , Analgesics, Non-Narcotic/pharmacology , Animals , Biotransformation/drug effects , Blood-Brain Barrier , Chronic Disease , Dipeptides/analysis , Dipeptides/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Extracellular Fluid/chemistry , Injections, Intraperitoneal , Ligation , Male , Microdialysis , Models, Animal , Neuralgia/etiology , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacokinetics , Neuroprotective Agents/pharmacology , Organophosphorus Compounds/administration & dosage , Organophosphorus Compounds/pharmacokinetics , Organophosphorus Compounds/pharmacology , Pain Threshold/drug effects , Pyridazines/pharmacology , Quinolines/pharmacology , Rats , Rats, Sprague-Dawley , Rats, Wistar , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Receptors, Metabotropic Glutamate/physiology , Sciatic Nerve/injuriesABSTRACT
There is increasing evidence for the involvement of glutamate-mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD). We suggest that glutamate receptors of the N-methyl-D-aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner in this disorder. This continuous mild activation may lead to neuronal damage and impairment of synaptic plasticity (learning). It is likely that under such conditions Mg(2+) ions, which block NMDA receptors under normal resting conditions, can no longer do so. We found that overactivation of NMDA receptors using a direct agonist or a decrease in Mg(2+) concentration produced deficits in synaptic plasticity (in vivo: passive avoidance test and/or in vitro: LTP in the CA1 region). In both cases, memantine-an uncompetitive NMDA receptor antagonists with features of an 'improved' Mg(2+) (voltage-dependency, kinetics, affinity)-attenuated this deficit. Synaptic plasticity was restored by therapeutically-relevant concentrations of memantine (1 microM). Moreover, doses leading to similar brain/serum levels provided neuroprotection in animal models relevant for neurodegeneration in AD such as neurotoxicity produced by inflammation in the NBM or beta-amyloid injection to the hippocampus. As such, if overactivation of NMDA receptors is present in AD, memantine would be expected to improve both symptoms (cognition) and to slow down disease progression because it takes over the physiological function of magnesium.